Evidence map›Paper›PMID 34559359›Full record

Trial reportAdvances in therapy2021

Sedation Effects Produced by a Ciprofol Initial Infusion or Bolus Dose Followed by Continuous Maintenance Infusion in Healthy Subjects: A Phase 1 Trial.

Chao Hu, Xiaofeng Ou, Yi Teng, Shiqing Shu, Ying Wang, Xiaohong Zhu, Yan Kang, Jia Miao

2 registry-linked trialsAbstract readClinical Trial, Phase IRandomized Controlled Trial
In one paragraph

Trial report in Advances in therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 62 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07294989 recruitingnot on this mapstarted 2025, after this paper: background citation

Median Effective Concentration of Ciprofol and Its Correlation With Bispectral Index: A Prospective Observational Study

Typeobservational_patient_registrySponsorPeking University Shenzhen HospitalRan2025 to 2026Enrolled101ConditionsThyroid DiseaseArmsCiprofol
NCT07462949 nacompletednot on this mapstarted 2026, after this paper: background citation

A Study on Median Effective Concentration of Ciprofol Combined With Remifentanil Via Target-controlled Infusion for Inhibiting Tracheal Intubation Stimulation Under qNOX Index Monitoring

TypeinterventionalSponsorGuangzhou General Hospital of Guangzhou Military CommandRan2026 to 2026Enrolled70ConditionsElective Surgery, Target Controlled Infusion (TCI), Noxious Stimuli, Tracheal Intubation StimulationArmsCipofol combined with remifentanil administered via target-controlled infusion
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Comparison of Ciprofol-Nalbuphine and Propofol-Nalbuphine Sedation During Painless Gastrointestinal Endoscopy: A Randomized Controlled Trial.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Trial
  7. Trial
  8. Comparison of the Safety and Efficacy of CiprofolCurrent medicinal chemistry · 2026
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chao Hu *Clinical Trials Center, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Wuhou District, Chengdu, 610041, China.
Xiaofeng Ou *Department of Intensive Care Unit, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Wuhou District, Chengdu, 610041, China.
Yi TengDepartment of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China.
Shiqing ShuClinical Trials Center, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Wuhou District, Chengdu, 610041, China.
Ying WangClinical Trials Center, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Wuhou District, Chengdu, 610041, China.
Xiaohong ZhuClinical Trials Center, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Wuhou District, Chengdu, 610041, China.
Yan KangDepartment of Intensive Care Unit, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Wuhou District, Chengdu, 610041, China. kangyan_hx@163.com.
Jia MiaoClinical Trials Center, West China Hospital, Sichuan University, No. 37 Guoxue Lane, Wuhou District, Chengdu, 610041, China. miaosiyi1971@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe effects of continuous infusions of ciprofol on its pharmacodynamic and pharmacokinetic properties and safety profiles in healthy Chinese subjects were evaluated.

methodsIn this open-label, randomized, two-way cross-over study, subjects received initial doses of continuous ciprofol/propofol as an infusion for 30 min in part 1 (n = 8) and a bolus dose in part 2 (n = 8) followed by maintenance infusions for a total of 4 h in part 1 and 12 h in part 2. Each subject participated in both parts with a washout time of at least 40 h.

resultsThe safety and tolerability parameters of ciprofol were similar to those of propofol, and all treatment-emergent adverse events were mild. The incidences of injection pain and respiratory depression in subjects given ciprofol were lower than those receiving propofol. The pharmacokinetic parameters C

conclusionCiprofol has potential for clinical application for continuous intravenous infusion to maintain sedation for 12 h with the same safety, tolerability and efficacy as propofol.

Indexed as

AnesthesiaPropofolCross-Over StudiesHealthy VolunteersHumansHypnotics and SedativesInfusions, IntravenousHypnotics and SedativesPropofolCiprofolPharmacodynamicsPharmacokineticsPropofolSafetySedation

Identifiers

PMID34559359
PMCPMC8523013

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.